View More Recent Stories
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
-
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
-
Viatris (VTRS) PT Lowered to $13 at Jefferies
-
Viatris (VTRS) PT Lowered to $10 at Piper Sandler
-
Increasing unusual call option volume: VTRS SRE LZ CNX SABR ATEC NICE ERJ COMM SEAT
-
Viatris Inc (VTRS) Misses Q4 EPS by 4c, provides guidance
-
Viatris Inc (VTRS) Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology
-
Viatris Inc (VTRS) Tops Q3 EPS by 7c
-
Viatris Inc (VTRS) Tops Q3 EPS by 7c, reaffirms guidance
-
Lexicon Pharma (LXRX) Announces Exclusive Licensing Agreement With Viatris (VTRS) for Sotagliflozin in All Markets Outside of the U.S. and Europe
-
Viatris Inc (VTRS) Reports Positive Top-line Results from Phase 3 Study of EFFEXOR in Japanese Adults with Generalized Anxiety Disorder (GAD)
-
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row
-
Piper Sandler Reiterates Neutral Rating on Viatris (VTRS)
-
Viatris Inc (VTRS) Announces the Pricing Terms of Maximum Tender Offer
-
Viatris (VTRS) PT Raised to $12 at BofA Securities
-
Viatris Inc (VTRS) Tops Q2 EPS by 1c, provides guidance
-
Jefferies Resumes Viatris (VTRS) at Buy
-
Viatris Inc (VTRS) Completes All Previously Announced Divestitures
-
Viatris Inc (VTRS) : U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation
-
Viatris Named to TIME’s World’s Most Sustainable Companies 2024 List
